



Cancer Prevention and Control CIRB Meeting Agenda

March 26, 2026

I. Continuing Review

A191901, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Version Date 03/20/25)

II. Continuing Review

A212102, Blinded Reference Set for Multicancer Early Detection Blood Tests (Version Date 07/21/25)

III. Continuing Review

A232301CD, AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (Version Date 12/12/25)

IV. Continuing Review

INT21-05-01, A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome (Version Date 11/06/25)

V. Continuing Review

MDA20-01-01, A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP) (Version Date 10/10/25)

VI. Continuing Review

S1703, Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer (Version Date 03/07/25)

VII. Continuing Review

URCC-21038, Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting (Version Date 02/24/25)

VIII. Continuing Review

URCC-22053, High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients (Version Date 07/11/25)

IX. Continuing Review

WF-1805CD, Implementation and Effectiveness Trial of HN-STAR (Version
Date 03/10/25)
